Pfizer is approaching the acquisition of Mitsira for $ 7.3 billion

Pfizer logo

The Financial Times reported that the American pharmaceutical company, Fayzer, is close to completing a possible acquisition deal on Mitsira, an emerging company in the field of obesity treatment, for about 7.3 billion dollars, as part of the giant pharmaceutical company seeking to enhance its production line after the failure of the weight loss drug that it developed and has a wide follow -up.

The British newspaper indicated that this deal may be announced on Monday.

The newspaper quoted well -informed sources as saying that Vazer will pay a $ 47.5 owners per share, an additional $ 22.5 if it achieved certain performance criteria.

Bloomberg News indicated that the price offered in this deal is more severe than the price of Mitsira’s share at the end of trading last Friday and was about 33 dollars.

Mitsera is part of a generation of promising startups that compete for a share of obesity drugs, which is worth billions of dollars.

The Pfizer’s deal will allow the MT-233 I to reach Mitsira, which is an injection to lose weight that helped patients to lose up to 8.4 percent of their weight in 36 days during a short experiment of the drug in the early stages of the experimental period.

It should be noted that the number of doses of this treatment is likely to be less than the doses of Novo Nordsek and Elie Lily, the pioneers in the obesity treatment market, allowing patients to move from weekly doses to monthly doses.

Pfizer expects to conclude two or three deals with a total value of $ 15 billion during the year to enhance its product portfolio, according to Bloomberg.

The setback that caused obesity treatments – which was the best opportunity for the company to enter the weight loss market – has increased pressure on CEO Albert Burla, while analysts expect the company to restore its position in the market by acquiring a smaller company specialized in weight loss medications.